1. Phylogeny  
   Mitogen‐activated protein kinase 7 (MAPK7), also known as ERK5, BMK1, or PRKM7, is a member of the MAP kinase family that belongs to the CMGC group of protein kinases. It is evolutionarily distinct from classical ERKs (such as ERK1/2), p38 kinases, and JNKs due to its unique long C‐terminal extension, which houses a transcriptional activation domain; this structural addition sets it apart phylogenetically from its paralogs (le2023thesignificanceof pages 1-3, paudel2021themek5erk5pathway pages 1-2). MAPK7 is observed in a wide range of eukaryotic organisms, indicating that it has evolved from a common ancestor and is conserved across mammalian species as well as more distantly related species, such as Caenorhabditis elegans where the orthologous kinase, SMA-5, regulates intestinal intermediate filament organization (geisler2023intermediatefilamentnetwork pages 1-2). Within the kinome, MAPK7 occupies a unique niche along the MEK5/ERK5 signaling axis, and its upstream activator, the MAP kinase kinase MAP2K5, is specific for its activation; notably, MAP2K5 and MAPK7 operate independently of the commonly studied MEK1/ERK1/2 route (paudel2021themek5erk5pathway pages 1-2, le2023thesignificanceof pages 1-3). These evolutionary relationships underscore an ancient signaling module that has diverged to fulfill specialized functions such as transcriptional regulation and cytoprotective signaling in diverse tissues, including the heart, endothelium, and muscle (le2023thesignificanceof pages 12-13, paudel2021themek5erk5pathway pages 21-21).
2. Reaction Catalyzed  
   MAPK7 functions as a serine/threonine protein kinase whose catalytic activity involves the transfer of the γ‐phosphate from ATP to specific serine or threonine residues on substrate proteins. The generalized chemical reaction can be summarized as:  
     ATP + [protein]–(L‑serine/threonine) → ADP + [protein]–(L‑serine/threonine)‐phosphate + H⁺  
   This phosphorylation event alters the conformation, activity, or subcellular localization of the substrate, thereby modulating downstream signaling pathways. MAPK7 phosphorylates key substrates such as MEF2C—a transcription factor that regulates gene expression during differentiation and proliferation—as well as SGK1 at Ser-78, which is essential for growth factor–induced cell cycle progression. In cardiomyocytes, MAPK7 also acts to suppress apoptosis by disrupting the interaction between PML and MDM2, thereby influencing p53/TP53 stability and activity (Information, paudel2021themek5erk5pathway pages 2-3, le2023thesignificanceof pages 13-13). The reaction mechanism, similar to other protein kinases, proceeds through the binding of ATP to the kinase’s catalytic cleft, followed by the coordination of divalent metal ions and subsequent nucleophilic attack by the hydroxyl group of the substrate’s serine or threonine residue (pei2023computationalanalysisof pages 1-2, moustardas2023mapkpathwaysin pages 1-3).
3. Cofactor Requirements  
   The catalytic activity of MAPK7 is dependent on the binding of ATP as a phosphate donor, a common requirement among protein kinases. In addition, map kinases typically require divalent metal ions such as Mg²⁺ to facilitate proper binding and orientation of ATP in the catalytic pocket. Although experimental details specific to MAPK7’s cofactor dependency are not extensively detailed in the provided context, the overall reaction mechanism for protein kinases, including the CMGC subfamily to which MAPK7 belongs, consistently shows a requirement for Mg²⁺ ions (pei2023computationalanalysisof pages 2-4, moustardas2023mapkpathwaysin pages 1-3).
4. Substrate Specificity  
   MAPK7 exhibits substrate specificity toward serine/threonine residues within target proteins that are critical for mediating its diverse biological functions. One well‐characterized substrate is the transcription factor MEF2C, whose phosphorylation is pivotal in mediating gene expression related to cell differentiation and survival. Additionally, MAPK7 phosphorylates SGK1 at Ser-78; this modification is necessary for growth factor–induced cell cycle progression (Information). The specificity of MAPK7 is determined not only by the primary sequence of substrates but also by docking motifs within the target proteins that interact with specific regions in the MAPK7 catalytic domain. The kinase is known to be regulated by signals emanating from receptors such as EGF receptors via a Ras‐independent, MAP2K5‐dependent pathway, further emphasizing its distinct substrate recognition mechanism compared to classical MAPKs like ERK1/2 (paudel2021themek5erk5pathway pages 1-2, le2023thesignificanceof pages 8-9). Although detailed consensus motifs analogous to the RxRxxp[ST] for other kinases are not explicitly provided in the context, the presence of a conserved TEY motif within the activation loop of MAPK7 and its requirement for precise phosphorylation events underscore its selective catalytic action (le2023thesignificanceof pages 3-4, paudel2021themek5erk5pathway pages 2-3).
5. Structure  
   MAPK7 is organized into multiple distinct domains that confer its dual functionality as both a kinase and a transcriptional activator. The protein features an N-terminal kinase domain that shares approximately 50% sequence identity with the classical ERK1/2 kinases. This kinase domain contains critical structural elements such as the ATP-binding site, catalytic loop (CL), and the activation loop that includes conserved phosphorylation sites (e.g., T218 and Y220, as well as additional regulatory sites) necessary for its catalytic activation by its specific upstream activator, MAP2K5 (le2023thesignificanceof pages 1-3, paudel2021themek5erk5pathway pages 1-2). One of the unique structural features of MAPK7 is its large C-terminal extension, which encompasses a transcriptional activation domain (TAD) along with a nuclear localization signal (NLS). This C-terminal region is responsible for mediating the nuclear translocation of MAPK7 upon activation and directly engaging in transcriptional regulation by interfacing with target transcription factors such as MEF2C (le2023thesignificanceof pages 7-8, paudel2021themek5erk5pathway pages 1-2).  
   Recent computational studies and AlphaFold predictions have illuminated additional features such as a CMGC-insert within the kinase domain and a distal C-terminal segment that appears to adopt an autoinhibitory conformation by interacting with the ATP-binding cleft, thereby modulating kinase activity (pei2023computationalanalysisof pages 10-12, pei2023computationalanalysisof pages 15-16). Key catalytic residues, including those involved in coordinating ATP and Mg²⁺ ions, as well as residues within docking sites for substrate recognition, have been conserved across species. The interplay between the catalytic domain and the transcriptional activation domain is central to the bifunctional role of MAPK7, enabling it to act as both a conventional kinase and a regulator of gene expression upon nuclear entry (le2023thesignificanceof pages 12-13, paudel2021themek5erk5pathway pages 17-18).
6. Regulation  
   MAPK7 is tightly regulated by a combination of upstream kinases, intramolecular autophosphorylation events, and interactions with regulatory proteins. Activation of MAPK7 is primarily driven by phosphorylation at its activation loop—specifically at residues within the TEY motif—by its dedicated upstream kinase, MAP2K5. This dual phosphorylation not only activates the kinase activity of MAPK7 but also initiates autophosphorylation events in the C-terminal region, which are essential for its nuclear translocation and transcriptional activation (le2023thesignificanceof pages 1-3, paudel2021themek5erk5pathway pages 1-2).  
   In addition to MAP2K5, alternative phosphorylation events can occur via kinases such as CDK1, CDK5, and ERK2 under specific cellular conditions including mitotic arrest or stress responses, thereby modulating MAPK7’s transcriptional and catalytic outputs. An important regulatory phosphorylation is at T733 within the C-terminal transactivation domain; when phosphorylated, this residue acts as a gatekeeper to promote nuclear localization and facilitate subsequent target gene activation, particularly of MEF2-dependent transcripts (paudel2021themek5erk5pathway pages 2-3, le2023thesignificanceof pages 4-5).  
   MAPK7 is also subject to interaction with molecular chaperones such as HSP90 and CDC37 under resting conditions, which maintain the kinase in a closed, inactive conformation. Upon activation, these interactions are disrupted, enabling MAPK7 to adopt an open conformation suitable for substrate binding and catalytic activity (paudel2021themek5erk5pathway pages 1-2). Negative regulation is exemplified in cardiomyocytes where MAPK7 interacts with STUB1/CHIP, promoting the ubiquitination and degradation of ICER-type isoforms of CREM, thus attenuating pro-apoptotic signals (Information, le2023thesignificanceof pages 13-13). Further regulation may involve feedback mechanisms modulated by post-translational modifications such as SUMOylation and ubiquitination, although detailed mapping of these regulatory modifications remains an active area of research (le2023thesignificanceof pages 11-12, paudel2021themek5erk5pathway pages 15-17).
7. Function  
   MAPK7 plays a central role in diverse biological processes by integrating extracellular signals into appropriate intracellular responses via its dual kinase and transcriptional activities. In proliferating cells, MAPK7 is activated by growth factors such as EGF through a Ras-independent but MAP2K5-dependent pathway, triggering nuclear translocation where it phosphorylates transcription factors like MEF2C to regulate gene expression programs important for differentiation and proliferation (Information, paudel2021themek5erk5pathway pages 1-2, le2023thesignificanceof pages 1-3).  
   In cardiomyocytes, MAPK7 exerts anti-apoptotic effects by engaging with STUB1/CHIP to promote the ubiquitination and degradation of ICER-type isoforms of CREM, thereby contributing to cell survival during stress (Information, le2023thesignificanceof pages 7-8). It also phosphorylates SGK1 at Ser-78, a modification that is required for growth factor–induced cell cycle progression, highlighting its role in regulating cellular proliferation (Information).  
   MAPK7 has been implicated in muscle cell differentiation, where its activation supports myogenic gene expression and differentiation processes, and it may be critical for maintaining endothelial function and vascular integrity. In endothelial cells, the activation of MAPK7 via mechanical stimuli such as laminar shear stress contributes to vasoprotective gene expression – for instance, the upregulation of Krüppel-like factors (KLF2 and KLF4) that support blood vessel integrity and anti-inflammatory responses (paudel2021themek5erk5pathway pages 7-9, le2023thesignificanceof pages 5-6). Moreover, MAPK7 is involved in the regulation of p53/TP53 function by disrupting the PML-MDM2 interaction, thereby impacting cell cycle checkpoints and apoptosis (Information, paudel2021themek5erk5pathway pages 2-3).  
   Collectively, MAPK7 serves as a bifunctional signaling mediator whose roles extend from cell cycle regulation and differentiation to cytoprotection in stress-responsive tissues, marking it as a promising target in therapeutic strategies for cancer, cardiovascular disease, and vascular disorders (le2023thesignificanceof pages 6-7, paudel2021themek5erk5pathway pages 15-17).
8. Other Comments  
   Currently, no clinical trials have been registered that specifically target MAPK7, indicating that the clinical development of inhibitors for this kinase is in its infancy or that efforts remain limited to preclinical studies (Clinical Trial Search: AREA[InterventionName]ERK5 OR AREA[InterventionName]MAPK7 OR AREA[InterventionName]BMK1 OR AREA[InterventionName]PRKM7 OR AREA[Condition]MAPK7 OR AREA[Condition]ERK5 OR AREA[Condition]BMK1 OR AREA[Condition]PRKM7). The Open Targets platform similarly reports only limited genetic associations for MAPK7, with a modest link to certain phenotypes such as carnitine measurement, suggesting that while MAPK7 is a promising target, its role in disease requires further elucidation (OpenTargets Search: -MAPK7).  
   Several inhibitors targeting ERK5/MAPK7 have been reported in the literature. For instance, compounds such as XMD8-92 have been used in preclinical settings to interrogate MAPK7’s function; however, some ERK5 inhibitors have paradoxical effects by inducing transcriptional activation, highlighting the complexity of its bifunctional regulation (paudel2021themek5erk5pathway pages 15-17, le2023thesignificanceof pages 13-13). These inhibitors are mainly used as research tools rather than as clinical candidates, and further optimization regarding specificity and efficacy is an active area of research.  
   Disease associations for MAPK7 include various cancers (such as melanoma, colon, and triple-negative breast cancer) where its activation serves as an escape mechanism during MAPK inhibitor treatment, as well as cardiovascular conditions in which MAPK7 contributes to endothelial survival and maintenance of vascular integrity. Additionally, its role in muscle differentiation and regulation of p53/TP53 signaling underscores its involvement in developmental and stress response pathways (Information, paudel2021themek5erk5pathway pages 2-3, le2023thesignificanceof pages 11-12). Notable mutations specific to MAPK7 have yet to be clearly defined, and current studies focus more on its regulation through post-translational modifications rather than on mutation-driven dysregulation.  
   Overall, MAPK7 remains a subject of intense basic and translational research due to its multifunctional roles and potential as a therapeutic target in diseases characterized by dysregulated cell growth, apoptosis, and stress responses (le2023thesignificanceof pages 5-6, paudel2021themek5erk5pathway pages 17-18).
9. References  
   Clinical Trial Search: AREA[InterventionName]ERK5 OR AREA[InterventionName]MAPK7 OR AREA[InterventionName]BMK1 OR AREA[InterventionName]PRKM7 OR AREA[Condition]MAPK7 OR AREA[Condition]ERK5 OR AREA[Condition]BMK1 OR AREA[Condition]PRKM7.  
   OpenTargets Search: -MAPK7.  
   le2023thesignificanceof pages 1-3, le2023thesignificanceof pages 12-12, le2023thesignificanceof pages 12-13, le2023thesignificanceof pages 7-8, le2023thesignificanceof pages 8-9, le2023thesignificanceof pages 11-12, le2023thesignificanceof pages 13-13, le2023thesignificanceof pages 3-4, le2023thesignificanceof pages 4-5, le2023thesignificanceof pages 5-6, le2023thesignificanceof pages 6-7, le2023thesignificanceof pages 9-11.  
   paudel2021themek5erk5pathway pages 1-2, paudel2021themek5erk5pathway pages 15-17, paudel2021themek5erk5pathway pages 17-18, paudel2021themek5erk5pathway pages 21-21, paudel2021themek5erk5pathway pages 9-10, paudel2021themek5erk5pathway pages 12-13, paudel2021themek5erk5pathway pages 13-15, paudel2021themek5erk5pathway pages 15-17, paudel2021themek5erk5pathway pages 18-19, paudel2021themek5erk5pathway pages 19-21, paudel2021themek5erk5pathway pages 2-3, paudel2021themek5erk5pathway pages 3-5, paudel2021themek5erk5pathway pages 7-9.  
   pei2023computationalanalysisof pages 1-2, pei2023computationalanalysisof pages 10-12, pei2023computationalanalysisof pages 15-16, pei2023computationalanalysisof pages 2-4.  
   moustardas2023mapkpathwaysin pages 1-3, moustardas2023mapkpathwaysin pages 3-4.  
   orand2023revealingthemechanism pages 33-38, orand2023revealingthemechanism pages 38-41, orand2023revealingthemechanism pages 56-59.  
   geisler2023intermediatefilamentnetwork pages 1-2, geisler2023intermediatefilamentnetwork pages 23-24.

References

1. (Clinical Trial Search: AREA[InterventionName]ERK5 OR AREA[InterventionName]MAPK7 OR AREA[InterventionName]BMK1 OR AREA[InterventionName]PRKM7 OR AREA[Condition]MAPK7 OR AREA[Condition]ERK5 OR AREA[Condition]BMK1 OR AREA[Condition]PRKM7): Clinical Trials Search via ClinicalTrials.gov: AREA[InterventionName]ERK5 OR AREA[InterventionName]MAPK7 OR AREA[InterventionName]BMK1 OR AREA[InterventionName]PRKM7 OR AREA[Condition]MAPK7 OR AREA[Condition]ERK5 OR AREA[Condition]BMK1 OR AREA[Condition]PRKM7
2. (OpenTargets Search: -MAPK7): Open Targets Query (-MAPK7, 1 results). Ochoa, D. et al. (2023). The next-generation Open Targets Platform: reimagined, redesigned, rebuilt. Nucleic Acids Research.
3. (le2023thesignificanceof pages 1-3): Nhat-Tu Le. The significance of erk5 catalytic-independent functions in disease pathways. Frontiers in Cell and Developmental Biology, Aug 2023. URL: https://doi.org/10.3389/fcell.2023.1235217, doi:10.3389/fcell.2023.1235217. This article has 5 citations and is from a peer-reviewed journal.
4. (le2023thesignificanceof pages 12-12): Nhat-Tu Le. The significance of erk5 catalytic-independent functions in disease pathways. Frontiers in Cell and Developmental Biology, Aug 2023. URL: https://doi.org/10.3389/fcell.2023.1235217, doi:10.3389/fcell.2023.1235217. This article has 5 citations and is from a peer-reviewed journal.
5. (le2023thesignificanceof pages 12-13): Nhat-Tu Le. The significance of erk5 catalytic-independent functions in disease pathways. Frontiers in Cell and Developmental Biology, Aug 2023. URL: https://doi.org/10.3389/fcell.2023.1235217, doi:10.3389/fcell.2023.1235217. This article has 5 citations and is from a peer-reviewed journal.
6. (le2023thesignificanceof pages 7-8): Nhat-Tu Le. The significance of erk5 catalytic-independent functions in disease pathways. Frontiers in Cell and Developmental Biology, Aug 2023. URL: https://doi.org/10.3389/fcell.2023.1235217, doi:10.3389/fcell.2023.1235217. This article has 5 citations and is from a peer-reviewed journal.
7. (le2023thesignificanceof pages 8-9): Nhat-Tu Le. The significance of erk5 catalytic-independent functions in disease pathways. Frontiers in Cell and Developmental Biology, Aug 2023. URL: https://doi.org/10.3389/fcell.2023.1235217, doi:10.3389/fcell.2023.1235217. This article has 5 citations and is from a peer-reviewed journal.
8. (paudel2021themek5erk5pathway pages 1-2): Rupesh Paudel, Lorenza Fusi, and Marc Schmidt. The mek5/erk5 pathway in health and disease. International Journal of Molecular Sciences, 22:7594, Jul 2021. URL: https://doi.org/10.3390/ijms22147594, doi:10.3390/ijms22147594. This article has 69 citations and is from a peer-reviewed journal.
9. (paudel2021themek5erk5pathway pages 15-17): Rupesh Paudel, Lorenza Fusi, and Marc Schmidt. The mek5/erk5 pathway in health and disease. International Journal of Molecular Sciences, 22:7594, Jul 2021. URL: https://doi.org/10.3390/ijms22147594, doi:10.3390/ijms22147594. This article has 69 citations and is from a peer-reviewed journal.
10. (paudel2021themek5erk5pathway pages 17-18): Rupesh Paudel, Lorenza Fusi, and Marc Schmidt. The mek5/erk5 pathway in health and disease. International Journal of Molecular Sciences, 22:7594, Jul 2021. URL: https://doi.org/10.3390/ijms22147594, doi:10.3390/ijms22147594. This article has 69 citations and is from a peer-reviewed journal.
11. (paudel2021themek5erk5pathway pages 21-21): Rupesh Paudel, Lorenza Fusi, and Marc Schmidt. The mek5/erk5 pathway in health and disease. International Journal of Molecular Sciences, 22:7594, Jul 2021. URL: https://doi.org/10.3390/ijms22147594, doi:10.3390/ijms22147594. This article has 69 citations and is from a peer-reviewed journal.
12. (paudel2021themek5erk5pathway pages 9-10): Rupesh Paudel, Lorenza Fusi, and Marc Schmidt. The mek5/erk5 pathway in health and disease. International Journal of Molecular Sciences, 22:7594, Jul 2021. URL: https://doi.org/10.3390/ijms22147594, doi:10.3390/ijms22147594. This article has 69 citations and is from a peer-reviewed journal.
13. (le2023thesignificanceof pages 11-12): Nhat-Tu Le. The significance of erk5 catalytic-independent functions in disease pathways. Frontiers in Cell and Developmental Biology, Aug 2023. URL: https://doi.org/10.3389/fcell.2023.1235217, doi:10.3389/fcell.2023.1235217. This article has 5 citations and is from a peer-reviewed journal.
14. (le2023thesignificanceof pages 13-13): Nhat-Tu Le. The significance of erk5 catalytic-independent functions in disease pathways. Frontiers in Cell and Developmental Biology, Aug 2023. URL: https://doi.org/10.3389/fcell.2023.1235217, doi:10.3389/fcell.2023.1235217. This article has 5 citations and is from a peer-reviewed journal.
15. (le2023thesignificanceof pages 3-4): Nhat-Tu Le. The significance of erk5 catalytic-independent functions in disease pathways. Frontiers in Cell and Developmental Biology, Aug 2023. URL: https://doi.org/10.3389/fcell.2023.1235217, doi:10.3389/fcell.2023.1235217. This article has 5 citations and is from a peer-reviewed journal.
16. (le2023thesignificanceof pages 4-5): Nhat-Tu Le. The significance of erk5 catalytic-independent functions in disease pathways. Frontiers in Cell and Developmental Biology, Aug 2023. URL: https://doi.org/10.3389/fcell.2023.1235217, doi:10.3389/fcell.2023.1235217. This article has 5 citations and is from a peer-reviewed journal.
17. (le2023thesignificanceof pages 5-6): Nhat-Tu Le. The significance of erk5 catalytic-independent functions in disease pathways. Frontiers in Cell and Developmental Biology, Aug 2023. URL: https://doi.org/10.3389/fcell.2023.1235217, doi:10.3389/fcell.2023.1235217. This article has 5 citations and is from a peer-reviewed journal.
18. (le2023thesignificanceof pages 6-7): Nhat-Tu Le. The significance of erk5 catalytic-independent functions in disease pathways. Frontiers in Cell and Developmental Biology, Aug 2023. URL: https://doi.org/10.3389/fcell.2023.1235217, doi:10.3389/fcell.2023.1235217. This article has 5 citations and is from a peer-reviewed journal.
19. (le2023thesignificanceof pages 9-11): Nhat-Tu Le. The significance of erk5 catalytic-independent functions in disease pathways. Frontiers in Cell and Developmental Biology, Aug 2023. URL: https://doi.org/10.3389/fcell.2023.1235217, doi:10.3389/fcell.2023.1235217. This article has 5 citations and is from a peer-reviewed journal.
20. (paudel2021themek5erk5pathway pages 12-13): Rupesh Paudel, Lorenza Fusi, and Marc Schmidt. The mek5/erk5 pathway in health and disease. International Journal of Molecular Sciences, 22:7594, Jul 2021. URL: https://doi.org/10.3390/ijms22147594, doi:10.3390/ijms22147594. This article has 69 citations and is from a peer-reviewed journal.
21. (paudel2021themek5erk5pathway pages 13-15): Rupesh Paudel, Lorenza Fusi, and Marc Schmidt. The mek5/erk5 pathway in health and disease. International Journal of Molecular Sciences, 22:7594, Jul 2021. URL: https://doi.org/10.3390/ijms22147594, doi:10.3390/ijms22147594. This article has 69 citations and is from a peer-reviewed journal.
22. (paudel2021themek5erk5pathway pages 18-19): Rupesh Paudel, Lorenza Fusi, and Marc Schmidt. The mek5/erk5 pathway in health and disease. International Journal of Molecular Sciences, 22:7594, Jul 2021. URL: https://doi.org/10.3390/ijms22147594, doi:10.3390/ijms22147594. This article has 69 citations and is from a peer-reviewed journal.
23. (paudel2021themek5erk5pathway pages 19-21): Rupesh Paudel, Lorenza Fusi, and Marc Schmidt. The mek5/erk5 pathway in health and disease. International Journal of Molecular Sciences, 22:7594, Jul 2021. URL: https://doi.org/10.3390/ijms22147594, doi:10.3390/ijms22147594. This article has 69 citations and is from a peer-reviewed journal.
24. (paudel2021themek5erk5pathway pages 2-3): Rupesh Paudel, Lorenza Fusi, and Marc Schmidt. The mek5/erk5 pathway in health and disease. International Journal of Molecular Sciences, 22:7594, Jul 2021. URL: https://doi.org/10.3390/ijms22147594, doi:10.3390/ijms22147594. This article has 69 citations and is from a peer-reviewed journal.
25. (paudel2021themek5erk5pathway pages 3-5): Rupesh Paudel, Lorenza Fusi, and Marc Schmidt. The mek5/erk5 pathway in health and disease. International Journal of Molecular Sciences, 22:7594, Jul 2021. URL: https://doi.org/10.3390/ijms22147594, doi:10.3390/ijms22147594. This article has 69 citations and is from a peer-reviewed journal.
26. (paudel2021themek5erk5pathway pages 7-9): Rupesh Paudel, Lorenza Fusi, and Marc Schmidt. The mek5/erk5 pathway in health and disease. International Journal of Molecular Sciences, 22:7594, Jul 2021. URL: https://doi.org/10.3390/ijms22147594, doi:10.3390/ijms22147594. This article has 69 citations and is from a peer-reviewed journal.
27. (pei2023computationalanalysisof pages 1-2): Jimin Pei and Qian Cong. Computational analysis of regulatory regions in human protein kinases. Protein Science, Sep 2023. URL: https://doi.org/10.1002/pro.4764, doi:10.1002/pro.4764. This article has 3 citations and is from a peer-reviewed journal.
28. (pei2023computationalanalysisof pages 10-12): Jimin Pei and Qian Cong. Computational analysis of regulatory regions in human protein kinases. Protein Science, Sep 2023. URL: https://doi.org/10.1002/pro.4764, doi:10.1002/pro.4764. This article has 3 citations and is from a peer-reviewed journal.
29. (pei2023computationalanalysisof pages 15-16): Jimin Pei and Qian Cong. Computational analysis of regulatory regions in human protein kinases. Protein Science, Sep 2023. URL: https://doi.org/10.1002/pro.4764, doi:10.1002/pro.4764. This article has 3 citations and is from a peer-reviewed journal.
30. (moustardas2023mapkpathwaysin pages 1-3): Petros Moustardas, Daniel Aberdam, and Neil Lagali. Mapk pathways in ocular pathophysiology: potential therapeutic drugs and challenges. Cells, 12:617, Feb 2023. URL: https://doi.org/10.3390/cells12040617, doi:10.3390/cells12040617. This article has 37 citations and is from a peer-reviewed journal.
31. (moustardas2023mapkpathwaysin pages 3-4): Petros Moustardas, Daniel Aberdam, and Neil Lagali. Mapk pathways in ocular pathophysiology: potential therapeutic drugs and challenges. Cells, 12:617, Feb 2023. URL: https://doi.org/10.3390/cells12040617, doi:10.3390/cells12040617. This article has 37 citations and is from a peer-reviewed journal.
32. (orand2023revealingthemechanism pages 33-38): T Orand. Revealing the mechanism of action of intrinsically disordered proteins in mapk cell signalling. Unknown journal, 2023.
33. (orand2023revealingthemechanism pages 38-41): T Orand. Revealing the mechanism of action of intrinsically disordered proteins in mapk cell signalling. Unknown journal, 2023.
34. (pei2023computationalanalysisof pages 2-4): Jimin Pei and Qian Cong. Computational analysis of regulatory regions in human protein kinases. Protein Science, Sep 2023. URL: https://doi.org/10.1002/pro.4764, doi:10.1002/pro.4764. This article has 3 citations and is from a peer-reviewed journal.
35. (geisler2023intermediatefilamentnetwork pages 1-2): Florian Geisler, Sanne Remmelzwaal, Vera Jankowski, Ruben Schmidt, Mike Boxem, and Rudolf E Leube. Intermediate filament network perturbation in the c. elegans intestine causes systemic dysfunctions. eLife, Jun 2023. URL: https://doi.org/10.7554/elife.82333, doi:10.7554/elife.82333. This article has 5 citations and is from a domain leading peer-reviewed journal.
36. (geisler2023intermediatefilamentnetwork pages 23-24): Florian Geisler, Sanne Remmelzwaal, Vera Jankowski, Ruben Schmidt, Mike Boxem, and Rudolf E Leube. Intermediate filament network perturbation in the c. elegans intestine causes systemic dysfunctions. eLife, Jun 2023. URL: https://doi.org/10.7554/elife.82333, doi:10.7554/elife.82333. This article has 5 citations and is from a domain leading peer-reviewed journal.
37. (orand2023revealingthemechanism pages 56-59): T Orand. Revealing the mechanism of action of intrinsically disordered proteins in mapk cell signalling. Unknown journal, 2023.